< PreviousGood reasons for membership: •Society’s journal: CMI •Registration discounts for events •Participation in study groups •ESCMID Newsletter and Yearbook •Discounts to other journals •Access to the eLibrary and membership directory •Eligibility for ESCMID awards, research grants, observerships and mentorships •Right to vote and participate in ESCMID Apply for membership www.escmid.org/membership escmidmembership@escmid.org Join us today– our commitment is infectious! Become an ESCMID member Sign up for study groups – – VISIT US in the ESCMID WORLD at ECCMID Lisbon41 INTEGRATED SYMPOSIA 32nd ECCMID Lisbon, Portugal – INTEGRATED SYMPOSIA AND EXHIBITION GUIDE IS2212:15 - 13:15Integrated Symposium Hall P Time to rethink NTM: understanding your at-risk MAC-PD patients and optimising their outcomes ChairMateja Jankovic Makek (Zagreb, Croatia) ESCMID-appointed chairDaniela Maria Cirillo (Milan, Italy) I11012:15Welcome and introduction Daniela Maria Cirillo (Milan, Italy) Mateja Jankovic Makek (Zagreb, Croatia) I11112:20Understanding pulmonary and non-pulmonary risk factors for developing MAC-PD Michael Loebinger (London, United Kingdom) I11212:32The role of clinical microbiologist in the diagnosis of MAC-PD Jakko Van Ingen (Nijmegen, Netherlands) I11312:47Therapeutic interventions and likelihood of clinical success or progress into refractory disease, include real-life cases Nicolas Veziris (Paris, France) I11413:05Panel discussion and Q&A Daniela Maria Cirillo (Milan, Italy) Mateja Jankovic Makek (Zagreb, Croatia) Co-organised with:Insmed Sunday, 24 April 20224232nd ECCMID Lisbon, Portugal – INTEGRATED SYMPOSIA AND EXHIBITION GUIDE IS2312:15 - 13:15Integrated Symposium Hall Q Intravenous fosfomycin: comprehensive new data evaluation for this WHO essential antibiotic for treatment of adult and pediatric patients with severe infections ChairMarkus Zeitlinger (Vienna, Austria) ESCMID-appointed chairSebastian Wicha (Hamburg, Germany) I11512:15Welcome and introduction Sebastian Wicha (Hamburg, Germany) Markus Zeitlinger (Vienna, Austria) I11612:20IV fosfomycin´s role in the treatment of infections caused by MDR Gram- negative pathogens Marco Falcone (Pisa, Italy) I11712:40IV fosfomycin´s role in the treatment of infections caused by Gram-positive pathogens Stefan Hagel (Jena, Germany) I11813:00Panel discussion and Q&A Sebastian Wicha (Hamburg, Germany) Markus Zeitlinger (Vienna, Austria) Co-organised with:InfectoPharm Arzneimittel und Consilium GmbH Sunday, 24 April 202243 INTEGRATED SYMPOSIA 32nd ECCMID Lisbon, Portugal – INTEGRATED SYMPOSIA AND EXHIBITION GUIDE IS2413:30 - 15:30Integrated Symposium Hall L Optimising treatment of invasive fungal infections in critically ill patients ChairPatricia Munoz (Madrid, Spain) ESCMID-appointed chairThierry Calandra (Lausanne, Switzerland) I11913:30Welcome and introduction Thierry Calandra (Lausanne, Switzerland) Patricia Munoz (Madrid, Spain) I12013:40Diagnostic challenges – capabilities for timely diagnosis of IFI in the ICU & ECMM global survey of diagnostic capacity Martin Hönigl (Graz, Austria) I12114:00Spectrum of activity of antifungal treatments & clinical implementation of MIC distributions Cornelia Lass-Flörl (Innsbruck, Austria) I12214:20Principles for assessing antifungal tissue distribution, fungicidal vs. fungistatic attributes of antifungal treatments in deep-seated IFI/biofilms Russel Lewis (Bologna, Italy) I12314:40Practical considerations in the management of antifungal treatment – drug- drug interactions and safety profile considerations Johan Maertens (Leuven, Belgium) I12415:00Panel discussion and Q&A Thierry Calandra (Lausanne, Switzerland) Patricia Munoz (Madrid, Spain) I12515:20Summary/Meeting Close Thierry Calandra (Lausanne, Switzerland) Patricia Munoz (Madrid, Spain) Co-organised with:Gilead Sciences Europe Ltd Sunday, 24 April 20224432nd ECCMID Lisbon, Portugal – INTEGRATED SYMPOSIA AND EXHIBITION GUIDE IS2513:30 - 15:30Integrated Symposium Hall N Moving insights into action: how innovative rapid diagnostics impact treatment decisions ChairTBA ESCMID-appointed chairTBA I12613:30Welcome and introduction TBA TBA I12713:35Status of HIV drug resistance – HIV-1 genotyping of the Integrase region to understand evolving drug resistance Chika Onwuamah (Lagos, Nigeria) I12813:55SARS-CoV-2 whole genome sequencing for emerging variant surveillance Rob Schuurman (Utrecht, Netherlands) I12914:15Antibiotic treatment duration - when less is more Evangelos Giamarellos-Bourboulis (Athens, Greece) I13014:35Challenges and opportunities in early recognition of sepsis: how structured processes can help? Laura Evans (Washington, United States) I13114:55Time is everything – opportunities for improving antimicrobial therapy in severe infections Jan De Waele (Gent, Belgium) I13215:15Panel discussion and Q&A TBA TBA Co-organised with:Thermo Fisher Scientific Sunday, 24 April 202245 INTEGRATED SYMPOSIA 32nd ECCMID Lisbon, Portugal – INTEGRATED SYMPOSIA AND EXHIBITION GUIDE IS25A13:30 - 15:30Integrated Symposium Hall O Evolution of rapid metagenomics for infectious disease applications ChairJustin O’Grady (Norwich, United Kingdom) ESCMID-appointed chairTBA INT713:30Welcome and introduction Justin O’Grady (Norwich, United Kingdom) TBA INT1613:35INHALE project - the potential of metagenomics for management of HAP and VAP in a critical care setting Virve Irene Enne (London, United Kingdom) INT1713:55Same-day respiratory metagenomics: beyond culture Jonathan Edgeworth (London, United Kingdom) INT1814:15Clinical metagenomics or the detection of antibiotic resistance: the next frontier? Etienne Ruppe (Paris, France) INT1914:35Towards rapid pathogen and AMR diagnostics for treatment of Spontaneous Bacterial Peritonitis (SBP) patients in a German hospital Alice Mchardy (Braunschweig, Germany) INT2014:55Panel discussion and Q&A Justin O’Grady (Norwich, United Kingdom) TBA I13915:25Closing remarks Justin O’Grady (Norwich, United Kingdom) TBA Co-organised with:Oxford Nanopore Technologies Sunday, 24 April 20224632nd ECCMID Lisbon, Portugal – INTEGRATED SYMPOSIA AND EXHIBITION GUIDE Sunday, 24 April 2022 IS2613:30 - 15:30Integrated Symposium Hall P Future-proofing mould disease diagnosis and treatment: the post-pandemic era ChairJohan Maertens (Leuven, Belgium) ESCMID-appointed chairDimitrios P. Kontoyiannis (Houston, United States) I13313:30Welcome and introduction Dimitrios P. Kontoyiannis (Houston, United States) Johan Maertens (Leuven, Belgium) I13413:35Emerging IMD trends from the ICU João Gonçalves Pereira (Vila Franca De Xira, Portugal) I13513:55Management of viral-associated aspergillosis in haematology patients Rosanne Sprute (Köln, Germany) I13614:15Challenges and solutions for the appropriate diagnosis of IMD in different patient populations Katrien Lagrou (Leuven, Belgium) I13714:35ECMO and renal replacement therapy (RRT) PK/PD real-world data Robert Krause (Graz, Austria) I13814:55Discussion and Q&A Dimitrios P. Kontoyiannis (Houston, United States) Johan Maertens (Leuven, Belgium) I13915:25Summary and closing remarks Dimitrios P. Kontoyiannis (Houston, United States) Johan Maertens (Leuven, Belgium) Co-organised with:Pfizer47 INTEGRATED SYMPOSIA 32nd ECCMID Lisbon, Portugal – INTEGRATED SYMPOSIA AND EXHIBITION GUIDE IS2713:30 - 15:30Integrated Symposium Hall Q COVID-19 today: outpatient treatment options and considerations ChairMaria Vehreschild (Frankfurt Am Main, Germany) ESCMID-appointed chairGraeme Ayton Meintjes (Observatory, South Africa) I14013:30Welcome and introduction Graeme Ayton Meintjes (Cape Town, South Africa) Maria Vehreschild (Frankfurt Am Main, Germany) I14113:40The evolving SARS-COV-2 pandemic: where we are today TBA I14214:00Early treatment of COVID-19: outpatient treatment options Milosz Parczewski (Szczecin, Poland) I14314:20Clinical considerations in the treatment of outpatients with COVID-19, a physician’s perspective Matteo Bassetti (Genoa, Italy) I14414:40Clinical considerations in the treatment of outpatients with COVID-19: a pharmacist’s perspective Nathan Everson (Roanoke, United States) I14515:00Q&A with audience Graeme Ayton Meintjes (Observatory, South Africa) Maria Vehreschild (Frankfurt Am Main, Germany) Co-organised with:MSD Sunday, 24 April 20224832nd ECCMID Lisbon, Portugal – INTEGRATED SYMPOSIA AND EXHIBITION GUIDE IS2816:15 - 18:15Integrated Symposium Hall L Innovative and scalable molecular solutions for infectious disease testing ChairLola Folgueira (Madrid, Spain) ESCMID-appointed chairColin R. Mackenzie (Düsseldorf, Germany) I14616:15Welcome and introduction Lola Folgueira (Madrid, Spain) Colin R. Mackenzie (Düsseldorf, Germany) I14716:20Improving syphilis screening by early detection using Treponema pallidum Transcription Mediated Amplification assay Helene Zondag (Amstelveen, Netherlands) I14816:50Paradigm shift in laboratory organisation Kelly Mertens (Rotterdam, Netherlands) I14917:20Performance of a quantitative CMV assay in allo-HSCT recipients Estela Giménez (Valencia, Spain) I15017:35Use of whole blood for the detection of CMV in transplant patients Sophie Alain (Limoges, France) INT1417:50Evaluation of analytical performance of saliva and urine specimens in a quantitative TMA assay for the detection of congenital CMV infection Sangeetha Nair (San Diego, United States) I15118:05Panel discussion and Q&A Lola Folgueira (Madrid, Spain) Colin R. Mackenzie (Düsseldorf, Germany) Co-organised with:Hologic Sunday, 24 April 202249 INTEGRATED SYMPOSIA 32nd ECCMID Lisbon, Portugal – INTEGRATED SYMPOSIA AND EXHIBITION GUIDE IS2916:15 - 18:15Integrated Symposium Hall N Reviewing 20 years of managing invasive mould infections: lessons learned and remaining challenges ChairSharon Chen (Sydney, Australia) ESCMID-appointed chairElio Castagnola (Genoa, Italy) I15216:15Welcome and introduction Elio Castagnola (Genoa, Italy) Sharon Chen (Sydney, Australia) I15316:20What have we achieved in invasive aspergillosis (IA) and what else is there still to do? Johan Maertens (Leuven, Belgium) I15416:45Why rare moulds are such a challenge and are we making a difference: experience from managing Lomentospora prolificans and Scedosporium infections Monica Slavin (Melbourne, Australia) I15517:10Better diagnostics or increased prevalence: why is coccidioidomycosis identification growing and what have we learned about management George Thompson (Davis, United States) I15617:35Panel discussion and Q&A Elio Castagnola (Genoa, Italy) Sharon Chen (Sydney, Australia) Co-organised with:F2G Ltd Sunday, 24 April 2022Next >